Movilax Powder for Solution: Each sachet of Movilax contains Polyethylene Glycol 3350 USP-NF13.125 g, Sodium chloride BP 350.7 mg, Sodium Bicarbonate BP 178.5 mg and Potassium Chloride BP 46.6 mg.
Polyethylene Glycol 3350 exerts an osmotic action in the gut, which induces a laxative effect. Polyethylene Glycol 3350 increases the stool volume, which triggers colon motility via neuromuscular pathways. Electrolytes combined with Polyethylene Glycol 3350 are exchanged across the intestinal barrier (mucosa) with serum electrolytes and excreted in fecal water without net gain or loss of sodium, potassium and water.
For effective relief from constipation and treatment of chronic constipation. Movilax is also effective in resolving fecal impaction.
Dosage & Administration
For adults and children aged 12 years and above
Constipation: The dose is 1 sachet daily. This may be increased to 2-3 sachets daily, if required.
8 sachets daily, consumed within 6 hours. A course of treatment for fecal impaction does not normally exceed 3 days.
Patients with renal insufficiency:
No dosage change is necessary for treatment of either constipation or fecal impaction.
Direction of use:
Each sachet should be dissolved in 125 ml water. For fecal impaction 8 sachets may be dissolved in 1 litre of water. Store the solution refrigerated and discard any solution not used within 6 hours.
Generally well tolerated. However side effects like allergic reactions, electrolyte disturbances particularly hyperkalaemia and hypokalaemia, abdominal pain, diarrhea, headache, peripheral edema may appear.
Patients with impaired cardiovascular function: For the treatment of fecal impaction the dose should be divided so that no more than two sachets are taken in any one hour.
If patients develop any symptoms indicating shifts of fluid/electrolytes (e.g. edema, shortness of breath, increasing fatigue, dehydration, cardiac failure) Movilax should be stopped immediately and any abnormality should be treated appropriately.
Prolonged use with all laxatives is undesirable and may lead to dependence.
Movilax is contraindicated in patients with known hypersensitivity to the active substance or any of the excipients, intestinal perforation or obstruction, crohn’s disease and ulcerative colitis.
Use in Pregnancy & Lactation
Use in Pregnancy:
There is no experience of the use of Polyethylene Glycol 3350 during pregnancy and lactation. It should only be used if considered essential by the physician.
Use in Lactation:
It is unknown whether Polyethylene Glycol 3350 is excreted in human breast milk.
No specific drug interactions have been found.
Severe pain or distention can be treated by nasogastric aspiration. Extensive fluid loss by diarrhea or vomiting may require correction of electrolyte disturbances.
Movilax Powder for Solution: Each box contains 20 Alu-Alu sachets of powder for solution.